In vivo, we observed similar anti-myeloma efficacy of BCMA CAR-iNKT cells that were either 41% CD4+ or 100% CD4+ (62) suggesting that CAR-iNKT function can occur across a range of CD4 expressing cells, though side by side comparisons of sorted cells in vivo could confirm this. This evidence concerns the gene CD4 and plasma cell myeloma.